KR920703081A - 자기항원의 에어로졸 투여에 의한 자기면역질환의 개선된 치료방법 - Google Patents

자기항원의 에어로졸 투여에 의한 자기면역질환의 개선된 치료방법

Info

Publication number
KR920703081A
KR920703081A KR1019920701486A KR920701486A KR920703081A KR 920703081 A KR920703081 A KR 920703081A KR 1019920701486 A KR1019920701486 A KR 1019920701486A KR 920701486 A KR920701486 A KR 920701486A KR 920703081 A KR920703081 A KR 920703081A
Authority
KR
South Korea
Prior art keywords
autoantigen
autoimmune disease
autoimmune
disease
treating
Prior art date
Application number
KR1019920701486A
Other languages
English (en)
Other versions
KR0185747B1 (ko
Inventor
알렌 하플러 데이비드
엘. 와이너 호워드
Original Assignee
원본미기재
브리겜 앤드 위민즈 하스피틀
오토이뮨, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 브리겜 앤드 위민즈 하스피틀, 오토이뮨, 인코포레이티드 filed Critical 원본미기재
Publication of KR920703081A publication Critical patent/KR920703081A/ko
Application granted granted Critical
Publication of KR0185747B1 publication Critical patent/KR0185747B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Rehabilitation Therapy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

내용 없음

Description

자기항원의 에어로졸 투여에 의한 자기면역질환의 개선된 치료방법
[도면의 간단한 설명]
제1도는 여러농도로 경구투여된 MBP가 EAE의 경과 및 위중도에 미치는 질병억압효과를 도시한 그래프임.
제2도는 여러농도로 에어로졸 형태로 투여된 MBP가 EAE의 경과 및 위중도에 미치는 질병억압효과를 도시한 그래프임.
제3(a-d)도는 GP-MBP를 경구 또는 에어로졸 형태로 투여한 경우 EAE의 경과 및 위중도에 미치는 여러가지 투여량의 효과를 직접 비교한 일련의 그래프임.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (18)

  1. 자기면역질환에 특이적으로 지향된 자기항원, 상기 자기항원의 자기면역질환 억압단편 및 상기 자기항원의 동족체중에서 선택된 한가지 이상을 상기 자기면역질환의 예방 또는 치료 유효량으로 하여 에어로졸 형태로서 자기면역질환에 걸린 포유동물에게 투여하는 것으로 됨을 특징으로 하는 포유동물에 있어서의 자기면역질환의 치료 또는 이의 발병을 예방하는 방법.
  2. 제1항에 있어서, 자기항원의 미엘린 염기성 단백질인 것이 특징인 방법.
  3. 제1항에 있어서, 자기항원이 클라겐인 것이 특징인 방법.
  4. 제1항에 있어서, 자기면역질환이 다발성 경화증인 것이 특징인 방법.
  5. 제1항에 있어서, 자기면역질환이 류마치스성 관절염인 것이 특징인 방법.
  6. 자기항원, 이 자기항원의 자기면역질환 억압단편 및 이 자기항원의 동족체중에서 선택된 한가지 이상을 상기 자기면역질환의 치료에 유효한 양으로 함유하는, 자기면역질환에 걸린 포유동물을 치료하기 위한 에어로졸 형태의 약리적 제제.
  7. 제6항에 있어서, 자기항원이 미엘린 염기성 단백질인 것이 특징인 제제.
  8. 제6항에 있어서, 자기항원이 콜라겐인 것이 특징인 제제.
  9. 제6항에 있어서, 자기항원이 미엘린 염기성 단백질의 자기면역질 환-억압단편인 것이 특징인 제제.
  10. 제6항에 있어서, 제약상 허용되는 담체 또는 희석제를 추가로 함유하는 것이 특징인 제제.
  11. 제6항에 있어서, 자기면역질환이 다발성 경화증인 것이 특징인 제제.
  12. 제6항에 있어서, 자기면역질환이 류마치스성 관절염인 것이 특징인 제제.
  13. 다발성 경화증 증상을 보이는 자기면역질환에 걸린 포유동물의 치료방법에 있어서, 상기 자기면역질환에 특이적인 자기항원, 상기 자기항원의 자기면역질환 억압단편 및 상기 자기항원의 동족체중에서 선택된 한가지 이상의 물질의 상기 질환억압 유효량을 에어로졸 형태로 하여 폐로(pulmonarytract)를 통해 상기 포유동물에게 투여하는 것으로 됨을 특징으로 하는 방법.
  14. 제13항에 있어서, 상기 자기항원이 미엘린 염기성 단백질인 것이 특징인 방법.
  15. 관절염 증상을 보이는 자기면역질환의 치료방법에 있어서, 상기 자기면역질환에 특이적인 자기항원, 상기 자기항원의 자기면역질환 억압단편 및 상기 자기항원의 동족체중에서 선택된 한가지 이상의 물질의 상기 질환억압 유효량을 에어로졸 형태로 투여하는 것을 특징으로 하는 방법.
  16. 제15항에 있어서, 상기 자기항원이 콜라겐인 것이 특징인 방법.
  17. 자기면역질환에 걸린 포유동물의 치료방법에 있어서, 자기면역질환에 특이적인 자기항원, 상기 자기항원의 자기면역질환 억압단편 및 상기 자기항원의 동족체중에서 선택된 한가지 이상의 물질을 함유하는 미세하게 분할된 스프레이의 상기 질환억압 유효량을 에어로졸 형태로 하여 상기 포유동물에게 폐로를 통해 공급하는 것으로 됨을 특징으로 하는 방법.
  18. 자기면역질환에 특이적인 자기항원, 상기 자기항원의 자기면역질환 억압단편 및 상기 자기항원의 동족체 중에서 선택된 한가지 이상의 물질을 함유하는 수성 에어로졸을 상기 자기면역질환 치료에 유효한 양으로 함유하는 약리적 제제.
    ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019920701486A 1989-12-20 1990-12-17 자기항원의 에어로졸 투여에 의한 자기면역질환의 개선된 치료방법 KR0185747B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45480689A 1989-12-20 1989-12-20
US454,806 1989-12-20
PCT/US1990/007455 WO1991008760A1 (en) 1989-12-20 1990-12-17 Improved treatment of autoimmune diseases by aerosol administration of auto antigens

Publications (2)

Publication Number Publication Date
KR920703081A true KR920703081A (ko) 1992-12-17
KR0185747B1 KR0185747B1 (ko) 1999-05-01

Family

ID=23806184

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920701486A KR0185747B1 (ko) 1989-12-20 1990-12-17 자기항원의 에어로졸 투여에 의한 자기면역질환의 개선된 치료방법

Country Status (14)

Country Link
EP (1) EP0506785B1 (ko)
JP (1) JP2625253B2 (ko)
KR (1) KR0185747B1 (ko)
AT (1) ATE190496T1 (ko)
AU (1) AU642693B2 (ko)
BR (1) BR9007950A (ko)
CA (1) CA2070281C (ko)
DE (1) DE69033487T2 (ko)
DK (1) DK0506785T3 (ko)
ES (1) ES2144398T3 (ko)
GR (1) GR3033634T3 (ko)
HU (2) HUT61487A (ko)
IL (1) IL96734A (ko)
WO (1) WO1991008760A1 (ko)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US6645504B1 (en) 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
ATE158950T1 (de) * 1989-07-14 1997-10-15 Autoimmune Inc Behandlung der autoimmunen uveoretinitis in menschen
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
WO1992006708A1 (en) * 1990-10-15 1992-04-30 Brigham And Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens
ATE228373T1 (de) * 1992-02-28 2002-12-15 Autoimmune Inc Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
EP0662838A4 (en) * 1992-09-25 1996-07-24 Autoimmune Inc PROCESS FOR THE TREATMENT OF RHUMATOID POLYARTHRITIS WITH TYPE II COLLAGEN.
CA2164326A1 (en) * 1993-06-02 1994-12-08 Wayne Robert Thomas Cryptic peptides for use in inducing immunologic tolerance
SI9520118A (sl) * 1994-10-25 1998-08-31 Immulogic Pharmaceutical Corporation Sestavki in zdravljenje multiple skleroze
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
DE69739275D1 (de) * 1996-01-05 2009-04-09 Autoimmune Inc Methode zur herstellung von type-ii kollagen
AUPO269996A0 (en) * 1996-10-01 1996-10-24 Walter And Eliza Hall Institute Of Medical Research, The A method of prophylaxis and treatment
CA2628857C (en) 1996-12-30 2011-09-13 Batelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
SE9902155L (sv) * 1999-06-09 2000-12-10 Bjoern Rydevik Serum antibodies
EP2295067A1 (en) 2000-05-24 2011-03-16 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services E-selectin for inducing immunotolerance
US7897575B2 (en) 2000-05-24 2011-03-01 The United States Of America As Represented By The Department Of Health And Human Services Treatment and prevention of vascular dementia
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
AU2003266081A1 (en) 2002-09-13 2004-04-30 Universite Laval Nucleoside triphosphate diphosphohydrolase (ntpdase 8) and uses thereof
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
EP1910410B1 (en) 2005-07-01 2011-10-26 Forsyth Dental Infirmary for Children Tuberculosis antigen detection assays and vaccines
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US20130236484A1 (en) 2012-03-08 2013-09-12 Detectogen Inc. Leishmaniasis antigen detection assays and vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US65734A (en) * 1867-06-11 Joseph fantou
US379778A (en) * 1888-03-20 Machine for mitering printers rules
DE3854741T3 (de) * 1987-06-24 2002-08-14 Autoimmune Inc Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
KR900700617A (ko) * 1988-04-08 1990-08-16 브루스 엠. 에이센 뼈 및 연골 유도 조성물

Also Published As

Publication number Publication date
CA2070281A1 (en) 1991-06-21
DE69033487T2 (de) 2000-06-29
KR0185747B1 (ko) 1999-05-01
HU9202072D0 (en) 1992-09-28
ATE190496T1 (de) 2000-04-15
ES2144398T3 (es) 2000-06-16
HU210715A9 (en) 1995-06-28
IL96734A0 (en) 1991-09-16
AU6979191A (en) 1991-07-18
JP2625253B2 (ja) 1997-07-02
EP0506785A4 (en) 1993-09-08
DE69033487D1 (de) 2000-04-20
EP0506785B1 (en) 2000-03-15
BR9007950A (pt) 1992-10-27
DK0506785T3 (da) 2000-07-24
AU642693B2 (en) 1993-10-28
EP0506785A1 (en) 1992-10-07
CA2070281C (en) 2005-08-23
JPH05504341A (ja) 1993-07-08
GR3033634T3 (en) 2000-10-31
WO1991008760A1 (en) 1991-06-27
IL96734A (en) 1996-11-14
HUT61487A (en) 1993-01-28

Similar Documents

Publication Publication Date Title
KR920703081A (ko) 자기항원의 에어로졸 투여에 의한 자기면역질환의 개선된 치료방법
NO931267L (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
BR9814499A (pt) Peptìdeo amida opióide sintético ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, processo para tratamento compreendendo a administração de uma quantidade da mesma
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ES2179190T3 (es) Inhalador dosificador para propianato de fluticasona.
BR9808786A (pt) Composto peptìdio cìclico ou um seu sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, processos para tratar doenças associadas com a regulagem do cálcio em um paciente e para tratar a osteopenia ou a osteoporose em um mamìfero hospedeiro
MX9305070A (es) Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
RU2220723C2 (ru) Средство и способ лечения или профилактики артериосклероза
BR9713141A (pt) Composição farmcêutica processo e kit para o tratamento ou a prevenção de um quadro fisiológico asociado com um distúrbio isquêmico relacionado com trombose e um paciente, uso de quantidades farmaceuticamente efetivas de um composto com atividade anti-xa e de um composto antagonista de agregação de plaquetas, produto contendo estes compostos, e, uso destes compostos.
BR9007527A (pt) Metodo para tratar ou prevenir a manifestacao clinica de uma doenca tendo os sintomas de uveoretinite e formulacao farmaceutica para tratar mamiferos sofrendo de uveoretinite
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
RU94045866A (ru) Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, способ лечения
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
VLIET-DASKALOPOULOU et al. Intra-articular rimexolone in the rheumatoid knee: a placebo-controlled, double-blind, multicentre trial of three doses
BR9611671A (pt) Método de alvejamento de dosagens de medicamentos e de agentes terapêuticos e de outros glicosaminoglicanos (gags) para tratar de uma doença ou condição em um ser humano.
BR0208920A (pt) Inibidor de aromatase em dose única para tratamento de infertilidade
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto
KR880009656A (ko) 국소 치근막 질환의 치료 또는 예방법
KR910700263A (ko) 시클로리노펩티드를 포함하는 의약
Saalbach et al. Antihypertensive efficacy, tolerance, and safety of ramipril in young vs. old patients: a retrospective study
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.
Pagliaro et al. Carbamazepine-induced Stevens-Johnson syndrome

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20091016

Year of fee payment: 12

EXPY Expiration of term